In Week of Mar 28, 2026, NGL Fine Chem Ltd (Pharma - Animal) is outperforming Nifty 500 with +72.0% relative strength. Fundamentals: Strong. On a 9-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: Three consecutive quarters of margin improvement (10.54% → 14.27% → 17.50%) driving PAT to 58.28% of operating profit
Impact: +₹10 Cr revenue
“PAT representing 58.28% of operating profit in Q3 FY26 versus 25.10% in Q3 FY25”
What: Nine-month FY26 revenues already exceeding 95.6% of full-year FY25 revenues with one quarter remaining
Impact: +₹20 Cr revenue
“Nine-month FY26 revenue of ₹351.96 crores, already surpassing 95.6% of full-year FY25 revenues”
What: Zero promoter pledging, debt-to-EBITDA of 0.91, and interest coverage exceeding 20 times
“Debt-to-EBITDA of 0.91 and interest coverage exceeding 20 times”
Earnings deceleration risks from management commentary
Trigger: Reversion to historical negative EBIT growth trend
Management view: EBIT CAGR of -5.13% over five years reflects historical profitability challenges despite 17.35% sales CAGR
Monitor: Q4 margin sustainability
Trigger: Additional regulatory-driven expenses becoming recurring
Management view: Considered a non-recurring, regulatory-driven impact
Monitor: Future employee cost trends
Key quotes from recent conference calls
“The company's ability to convert operating profit to net profit improved significantly, with PAT representing 58.28% of operating profit in Q3 FY26 versus just 25.10% in Q3 FY25, reflecting lower depreciation burden relative to EBITDA and stable interest costs. — Management”
“Revenue growth has been consistently strong across the last three quarters of FY26, with the company posting increases of 9.71%, 15.42%, and 6.03% sequentially. This translates to nine-month FY26 revenue of ₹351.96 crores, already surpassing 95.6% of full-year FY25 revenues with one quarter still remaining. — Management”
“Based on normalised earnings potential and peer comparisons, a fair value estimate for NGL Fine Chem centres around ₹1,800-1,900 per share, implying 15-18% downside from current levels. This valuation assumes the company maintains Q3 FY26 margin levels (17.50% operating margin) and achieves full-year FY26 net profit of approximately ₹40-45 crores. — Management”
Forward-looking targets from management for FY26
Implied PAT Growth
90%
OPM Guidance
17.5%
Key Milestones
• Maintain 17.5% OPM in Q4
• Achieve ₹40-45 crore full-year net profit
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +44% | +5% | Inflection Up |
| PAT (Net Profit) | +1500% | -25% | Inflection Up |
| OPM | 18.0% | +1200 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
NGL Fine Chem Ltd's latest quarterly results (Dec 2025) show
NGL Fine Chem Ltd's profit is growing with an turning around (inflection up) trend.
NGL Fine Chem Ltd's revenue growth trend is turning around (inflection up).
NGL Fine Chem Ltd's operating margin is volatile.
NGL Fine Chem Ltd's long-term compounding rates
NGL Fine Chem Ltd's earnings growth is turning around (inflection up) with positive momentum on a sequential basis.
NGL Fine Chem Ltd's trailing twelve month (TTM) performance
NGL Fine Chem Ltd appears significantly overvalued based on our fair value analysis.
NGL Fine Chem Ltd's current PE ratio is 37.4x.
NGL Fine Chem Ltd's current PE is 37.4x.
NGL Fine Chem Ltd's price-to-book ratio is 4.4x.
NGL Fine Chem Ltd is rated Strong with a fundamental score of 60.89/100. This score is calculated from objective financial metrics
NGL Fine Chem Ltd has a debt-to-equity ratio of N/A.
NGL Fine Chem Ltd's return ratios over recent years
NGL Fine Chem Ltd's operating cash flow is positive (FY2025).
NGL Fine Chem Ltd's current dividend yield is 0.08%.
NGL Fine Chem Ltd's shareholding pattern (Dec 2025)
NGL Fine Chem Ltd's promoter holding has remained stable recently.
NGL Fine Chem Ltd has been outperforming Nifty 500 for 9 consecutive weeks, indicating consistent outperformance.
NGL Fine Chem Ltd is an established outperformer with 9 weeks of consecutive Nifty 500 outperformance.
NGL Fine Chem Ltd has 3 key growth catalysts identified from recent earnings analysis
NGL Fine Chem Ltd has 2 key risks worth monitoring
In Q3 FY26, NGL Fine Chem Ltd's management highlighted
NGL Fine Chem Ltd's management has provided the following forward guidance for FY26
Based on quantitative research signals, here is why NGL Fine Chem Ltd may be worth studying
NGL Fine Chem Ltd investment thesis summary:
NGL Fine Chem Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
